Abstract

Granulocyte colony-stimulating factor (G-CSF), an endogenous hematopoietic growth factor, selectively stimulates granulopoietic cells of the neutrophil lineage [1]. G-CSF increases proliferation and differentiation of neutrophil progenitor cells, induces maturation of the progenitor cells, and enhances survival and function of mature neutrophils [2, 3]. Filgrastim is a recombinant methionyl form of human G-CSF (r-metHuG-CSF) produced in Escherichia coli and has been approved for the treatment of neutropenia in cancer patients receiving myelosuppressive chemotherapy, patients with acute myeloid leukemia (AML) receiving induction or consolidation chemotherapy, cancer patients receiving myeloablative chemotherapy followed by bone marrow transplantation, and patients with severe chronic neutropenia; filgrastim is also approved for mobilization of hematopoietic progenitor cells in patients undergoing peripheral blood progenitor cell (PBPC) collection and therapy [2, 3].

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.